Literature DB >> 24336032

Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.

Ruth Sapir-Pichhadze1, Yao Wang2, Olusegun Famure2, Yanhong Li2, S Joseph Kim3.   

Abstract

Wide variations in tacrolimus levels have been identified as a risk factor for inferior kidney allograft survival but past studies have not properly accounted for the dynamic nature of drug exposure over time. Here we evaluated whether time-varying exposure to tacrolimus increases the risk of long-term adverse outcomes in a retrospective cohort study in adult kidney transplant recipients on tacrolimus-based immunosuppression. Time-dependent Cox proportional hazards models were used to examine the association between the standard deviation of tacrolimus levels (TacSD) starting at 1-year post-transplant and the composite end point of late allograft rejection, transplant glomerulopathy, or total graft loss (including death). Among 356 patients, there was a significant 27% increase in the adjusted hazard of the composite end point for every 1-unit increase in TacSD (hazard ratio 1.27 (95% confidence interval 1.03, 1.56)). There was also a graded increase in the relative hazard for the composite end point by TacSD threshold (hazard ratios 1.33, 1.50, 1.84, and 2.56 for TacSD 1.5, 2, 2.5, and 3, respectively). The results were similar for total graft loss and the composite end point excluding death. Thus, increased time-dependent TacSD may be an independent risk factor for adverse kidney transplant outcomes. TacSD may serve as a monitoring tool to identify high-risk patients. Whether interventions to decrease TacSD will improve outcomes requires further study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24336032     DOI: 10.1038/ki.2013.465

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  51 in total

Review 1.  Understanding Medication Nonadherence after Kidney Transplant.

Authors:  Thomas E Nevins; Peter W Nickerson; Mary Amanda Dew
Journal:  J Am Soc Nephrol       Date:  2017-06-19       Impact factor: 10.121

Review 2.  Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.

Authors:  Simon Tremblay; Rita R Alloway
Journal:  AAPS J       Date:  2017-07-17       Impact factor: 4.009

3.  Slow Rise in Serum Creatinine Level in a Kidney Transplant Recipient 3 Years Post-Transplant.

Authors:  Margaret J Bia
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-23       Impact factor: 8.237

4.  Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial.

Authors:  John W McGillicuddy; Jessica L Chandler; Luke R Sox; David J Taber
Journal:  Ann Pharmacother       Date:  2020-06-08       Impact factor: 3.154

5.  Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.

Authors:  Stephan R Seibert; David P Schladt; Baolin Wu; Weihua Guan; Casey Dorr; Rory P Remmel; Arthur J Matas; Roslyn B Mannon; Ajay K Israni; William S Oetting; Pamala A Jacobson
Journal:  Clin Transplant       Date:  2018-10-31       Impact factor: 2.863

6.  Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.

Authors:  John A O'Regan; Mark Canney; Dervla M Connaughton; Patrick O'Kelly; Yvonne Williams; Geraldine Collier; Declan G deFreitas; Conall M O'Seaghdha; Peter J Conlon
Journal:  J Nephrol       Date:  2015-09-15       Impact factor: 3.902

7.  Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.

Authors:  Scott Davis; Jane Gralla; Patrick Klem; Suhong Tong; Gina Wedermyer; Brian Freed; Alexander Wiseman; James E Cooper
Journal:  Am J Transplant       Date:  2017-10-24       Impact factor: 8.086

8.  Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.

Authors:  David J Taber; Zemin Su; James N Fleming; John W McGillicuddy; Maria A Posadas-Salas; Frank A Treiber; Derek Dubay; Titte R Srinivas; Patrick D Mauldin; William P Moran; Prabhakar K Baliga
Journal:  Transplantation       Date:  2017-12       Impact factor: 4.939

9.  Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.

Authors:  Sonia Solomon; Adriana Colovai; Marcela Del Rio; Nicole Hayde
Journal:  Pediatr Nephrol       Date:  2019-11-15       Impact factor: 3.714

10.  The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study.

Authors:  David J Taber; Zemin Su; James N Fleming; Nicole A Pilch; Thomas Morinelli; Patrick Mauldin; Derek Dubay
Journal:  Transpl Int       Date:  2018-09-16       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.